Advanced in Non-Small Cell Lung Cancer (NSCLC)

Dr. John Ruckdeschel

Oncology
University Pathology Associates PLLC
2500 N State St, 
Jackson, MS 
Clinical Trials:Currently Recruiting for 1 Trial
Advanced in Non-Small Cell Lung Cancer (NSCLC)
University Pathology Associates PLLC
2500 N State St, 
Jackson, MS 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

John Ruckdeschel is an Oncologist in Jackson, Mississippi. Dr. Ruckdeschel is rated as an Advanced provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), and Lung Adenocarcinoma.

His clinical research consists of co-authoring 11 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 3 articles and participated in 11 clinical trials in the study of Non-Small Cell Lung Cancer (NSCLC).

Specialties
Oncology
Licenses
Internal Medicine in PA
Hospital Affiliations
Temple University Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

University Pathology Associates PLLC
2500 N State St, Jackson, MS 39216
Other Locations
Fox Chase Cancer Center
333 Cottman Ave, Philadelphia, PA 19111

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)
LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)
Enrollment Status: Recruiting
Publish Date: December 05, 2025
Intervention Type: Drug
Study Drug: Screening Platform
Study Phase: Phase 2/Phase 3
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
A Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab as First Line Therapy for Locally Advanced or Metastatic Non-squamous and Squamous Non-small Cell Lung Cancer Subjects (CANOPY-1)
A Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab as First Line Therapy for Locally Advanced or Metastatic Non-squamous and Squamous Non-small Cell Lung Cancer Subjects (CANOPY-1)
Enrollment Status: Active_not_recruiting
Publish Date: February 06, 2026
Intervention Type: Drug
Study Drugs: Canakinumab, Pembrolizumab, Carboplatin, Cisplatin, Paclitaxel, Nab-paclitaxel, Pemetrexed
Study Phase: Phase 3
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Enrollment Status: Active_not_recruiting
Publish Date: December 19, 2025
Intervention Type: Other, Drug
Study Drug: Crizotinib
Study Phase: Phase 3
A Randomized Phase II Trial of Carboplatin-Paclitaxel With or Without Ramucirumab in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma
A Randomized Phase II Trial of Carboplatin-Paclitaxel With or Without Ramucirumab in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma
Enrollment Status: Completed
Publish Date: October 30, 2025
Intervention Type: Drug, Biological
Study Drugs: Carboplatin, Paclitaxel, Ramucirumab
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled Pilot Study of an Oral, Selective Peripheral Opioid Receptor Antagonist in Advanced Non-Small Cell Lung Cancer
A Randomized, Double-Blind, Placebo-Controlled Pilot Study of an Oral, Selective Peripheral Opioid Receptor Antagonist in Advanced Non-Small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: July 17, 2025
Intervention Type: Other, Drug
Study Drug: Naloxegol
Study Phase: Phase 2
A Phase II Study of LOXO-292 in Patients With RET Fusion-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
A Phase II Study of LOXO-292 in Patients With RET Fusion-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
Enrollment Status: Active_not_recruiting
Publish Date: July 11, 2025
Intervention Type: Drug
Study Drug: Selpercatinib
Study Phase: Phase 2
A Phase II Study of Rucaparib in Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
A Phase II Study of Rucaparib in Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
Enrollment Status: Completed
Publish Date: May 21, 2025
Intervention Type: Drug
Study Drug: Rucaparib
Study Phase: Phase 2
A Phase II Study of Talazoparib Plus Avelumab in Patients With Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer Bearing Pathogenic STK11 Genomic Alterations (LUNG-MAP Sub-Study)
A Phase II Study of Talazoparib Plus Avelumab in Patients With Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer Bearing Pathogenic STK11 Genomic Alterations (LUNG-MAP Sub-Study)
Enrollment Status: Completed
Publish Date: September 03, 2024
Intervention Type: Drug
Study Drugs: Avelumab, Talazoparib, Talazoparib Tosylate
Study Phase: Phase 2
A Phase II Randomized Study of Ramucirumab Plus MK3475 (Pembrolizumab) Versus Standard of Care for Patients Previously Treated With Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)
A Phase II Randomized Study of Ramucirumab Plus MK3475 (Pembrolizumab) Versus Standard of Care for Patients Previously Treated With Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)
Enrollment Status: Completed
Publish Date: September 03, 2024
Intervention Type: Drug, Biological
Study Drugs: Docetaxel, Gemcitabine, Gemcitabine Hydrochloride, Pembrolizumab, Pemetrexed, Pemetrexed Disodium, Ramucirumab
Study Phase: Phase 2
A Phase 3, Controlled, Open-label, Randomized Study of RRx-001 Administered Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond Small Cell Lung Cancer
A Phase 3, Controlled, Open-label, Randomized Study of RRx-001 Administered Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond Small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: March 26, 2024
Intervention Type: Combination product, Drug
Study Drugs: RRx-001+eLOOP Device, Cisplatin+Carboplatin+Etoposide
Study Phase: Phase 3
View 12 Less Clinical Trials

11 Total Publications

Unstructured Data Are Superior to Structured Data for Eliciting Quantitative Smoking History From the Electronic Health Record.
Unstructured Data Are Superior to Structured Data for Eliciting Quantitative Smoking History From the Electronic Health Record.
Journal: JCO clinical cancer informatics
Published: February 22, 2023
Similar Doctors
Advanced in Non-Small Cell Lung Cancer (NSCLC)
Dr. Manubhai Patel
Oncology
Advanced in Non-Small Cell Lung Cancer (NSCLC)
Dr. Manubhai Patel
Oncology

Jackson Oncology Associates PLLC

2969 Curran Dr N Ste 200, 
Jackson, MS 
 (993.7 miles away)
601-355-2485
Languages Spoken:
English
See accepted insurances

Manubhai Patel is an Oncologist in Jackson, Mississippi. Dr. Patel is rated as a Distinguished provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, RUNX1 Familial Platelet Disorder, Paget Disease of the Breast, and Bone Marrow Aspiration.

Advanced in Non-Small Cell Lung Cancer (NSCLC)
Dr. Justin Baker
Oncology
Advanced in Non-Small Cell Lung Cancer (NSCLC)
Dr. Justin Baker
Oncology

Jackson Oncology Associates

1227 N State St Ste 101, 
Jackson, MS 
 (995.1 miles away)
601-355-2485
Languages Spoken:
English
See accepted insurances

Justin Baker is an Oncologist in Jackson, Mississippi. Dr. Baker is rated as a Distinguished provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Paget Disease of the Breast, RUNX1 Familial Platelet Disorder, Paris-Trousseau Thrombocytopenia, and Lung Cancer.

Advanced in Non-Small Cell Lung Cancer (NSCLC)
Dr. Grace Shumaker
Hematology | Oncology
Advanced in Non-Small Cell Lung Cancer (NSCLC)
Dr. Grace Shumaker
Hematology | Oncology

State Of Mississippi - University Of Mississippi Medical Center

2500 N State St, 
Jackson, MS 
 (994.3 miles away)
601-898-4404
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Grace Shumaker is a Hematologist and an Oncologist in Jackson, Mississippi. Dr. Shumaker is rated as a Distinguished provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). Her top areas of expertise are Paget Disease of the Breast, Polycythemia Vera, Inflammatory Breast Cancer, Pleuropulmonary Blastoma, and Bone Marrow Aspiration.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ruckdeschel's expertise for a condition
ConditionClose
      View All 8 Advanced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile